OncoMatch/Clinical Trials/NCT07803289
Biomarkers for Cancer Treatment
Is NCT07803289 recruiting? Yes, currently enrolling (Sep 2026).
Circulating biomarkers, such as miRNAs and proteomics, undergo identifiable and measurable changes during and following treatment for cancer, compared to pre-treatment baseline. Some of these changes may be associated either with known treatment parameters or predictive for cardiac or lung toxicity. The aim is to identify and validate changes following treatment for cancer, compared to pre-treatment baseline, as well as differential miRNA expression in two-group comparisons (patients receiving radical RT/chemoRT for thoracic cancers versus IO-based complex SACT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Cannot have received: chemotherapy
Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1)
Cannot have received: immunotherapy
Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1)
Cannot have received: radical radiation therapy or chemo-radiation therapy within the thorax
Use of radical RT or chemo-RT within the thorax in the last 5 years. (Cohort 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07803289 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify